Phase II pilot trial of dose-dense docetaxel followed by doxorubicin plus cyclophosphamide (T-AC) given as adjuvant or neoadjuvant treatment for women with node positive or high-risk primary breast cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 20 Aug 2008 Planned end date for this trial is now 1 Mar 2010 as reported by ClinicalTrials.gov
- 16 Oct 2005 New trial record.